Back Hepatitis B

Hepatitis B

FDA Approves Nivolumab Immunotherapy for Liver Cancer

In September, the U.S. Food and Drug Administration granted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumor activity, for people with hepatocellular carcinoma (HCC).

alt

Read more:

FDA Approves Nivolumab Immunotherapy for Liver Cancer

In September, the U.S. Food and Drug Administrationgranted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumor activity, for people with hepatocellular carcinoma (HCC).

alt

Read more:

EASL 2017: WHO Releases Global Hepatitis Report

An estimated 325 million people worldwide are living with chronic hepatitis B or hepatitis C, according to a new report from the World Health Organization (WHO) released at the EASL International Liver Congress last month in Amsterdam.Most lack access to testing and treatment, and therefore are at risk for liver disease progression, liver cancer, and death.

alt

Read more:

PAS 2017: Children on Immunosuppressive Therapy May Lose Hepatitis B Vaccine Protection

More than half of children treated with immunosuppressive drugs for gastrointestinal or rheumatological conditions no longer had protective levels of antibodies against hepatitis B virus (HBV) and may require repeat vaccinations, according to a study presented at the Pediatric Academic Societies Meeting last week in San Francisco.

alt

Read more:

Coverage of the 2017 EASL International Liver Congress

HIVandHepatitis.com coverage of the 2017 International Liver Congress, annual meeting of the European Society for the Study of the Liver, April 19-23, 2017, in Amsterdam.

alt

Read more:

EASL 2017: Albumin Reduces Complications of Decompensated Cirrhosis and Improves Survival

Long-term administration of human album was associated with fewer serious complications, less hospitalization, better quality of life, and longer survival for people with decompensated liver cirrhosis, according to a report at the EASL International Liver Congress last month in Amsterdam.

alt

Read more:

Coverage of the 2017 EASL International Liver Conference

HIVandHepatitis.com coverage of the 2017 International Liver Congress, annual meeting of the European Society for the Study of the Liver (EASL), April 19-23, 2017, in Amsterdam

Full coverage listing by topic

International Liver Congress website

4/30/17

alt

EASL 2017: Besifovir and Tenofovir Exalidex Look Promising for Hepatitis B

A pair of investigational nucleotide analog antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the EASL International Liver Congress last month in Amsterdam. Besifovir is in Phase 3 clinical trials, while tenofovir exalidex is in early development.

alt

Read more:

EASL 2017: EASL Releases Updated Hepatitis B Guidelines at International Liver Congress

The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection -- the first update since 2012 -- during a special session at its International Liver Congress last week in Amsterdam. For the first time the guidelines include tenofovir alafenamide (TAF) and present evidence about when and how to stop antiviral therapy.

alt

Read more: